 FARMINGTON HILLS, Mich., April 01, 2021 GLOBE NEWSWIRE -- Ocuphire Pharma, Inc. Nasdaq: OCUP, today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, approved an equity award under Ocuphires Inducement Plan, as a material inducement to Erik Sims in connection with his employment with the Company as Controller of the Company effective on April 1, 2021. The equity award was approved in accordance with Nasdaq Listing Rule 5635c4, which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan. 